CONCURRENT CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND DIABETES MELLITUS TYPE 2
- Authors: Sorokina L.1, Mineev V.1, Pavlova A.1, Nyoma M.1, Ivanov V.1, Trofimov V.1
-
Affiliations:
- Acad. I.P. Pavlov First Saint Petersburg State Medical University
- Issue: Vol 28, No 11 (2017)
- Pages: 33-35
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/117038
- ID: 117038
Cite item
Abstract
Full Text

About the authors
L. Sorokina
Acad. I.P. Pavlov First Saint Petersburg State Medical University
Email: lada_sorokina@mail.ru
V. Mineev
Acad. I.P. Pavlov First Saint Petersburg State Medical University
A. Pavlova
Acad. I.P. Pavlov First Saint Petersburg State Medical University
M. Nyoma
Acad. I.P. Pavlov First Saint Petersburg State Medical University
V. Ivanov
Acad. I.P. Pavlov First Saint Petersburg State Medical University
V. Trofimov
Acad. I.P. Pavlov First Saint Petersburg State Medical University
References
- Global Strategy for the Diagnosis, Management, and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2016.
- Agusti A. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don’t know (but should) // Proc. Am. Thorac. Soc. - 2007; 4 (7): 522-5.
- Glaser S., Kruger S., Merkel М. et al. Chronic Obstructive Pulmonary Disease and Diabetes Mellitus: A Systematic Review of the Literature // Respiration. - 2015; 89 (3): 253-64.
- Aparna A. Pulmonary Function Tests in Type 2 Diabetics and Non-Diabetic People - A Comparative Study // J. Clin. Diagnostic Research. - 2013; 7 (8): 1606-8.
- Ромашов Б.Б., Чернов А.В., Полякова Н.В. Хроническая обструктивная болезнь легких на фоне состояния инсулинорезистентности // Молодой ученый. - 2015; 14 (94): 80-4.
- Clini E., Crisafulli E., Radaeli A., et al. COPD and the metabolic syndrome: an intriguing assosiation // Int. Emerg. Med. - 2013; 8 (4): 283-9.
- Barnes P. Mediators of Chronic Obstructive Pulmonary Disease // Pharmacol. Rev. - 2004; 56 (4): 517-48.
- Adela R., Banerjee S. Role of inflammatory mediators in diabetes and cardiovascular diseases // Int. J. Sci. Technol. Manag. - 2015; 4 (01): 62-70.
- Spranger J., Kroke A., Mohlig M. et al. Inflammatory Cytokines and the Risk to Develop Type 2 Diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study // Diabetes. - 2003; 52: 812-7.
- Cazzola M., Matera M. IL-17 in chronic obstructive pulmonary disease // Exp. Rev. Respir. Med. - 2012; 6 (2): 135-8.
- Chen H., Ren X., Liao N. et al. Th17 cell frequency and IL-17A concentrations in peripheral blood mononuclear cells and vitreous fluid from patients with diabetic retinopathy // J. Int. Med. Res. - 2016; 44 (6): 1403-13.
- Imaoka H., Hoshino T., Takei S., et al. Interleukin-18 production and pulmonary function in COPD // Eur. Respir. J. - 2008; 31: 287-97.
- Hivert M., Sun Q., Shrader P. et al. Circulating IL-18 and the risk of type 2 diabetes in women // Diabetologia. - 2009; 52 (10): 2101-8.
- Abbas S. Comparative study of Interleukin-33 in Male with Chronic Obstructive Pulmonary Disease, Asthmatic Patients with Type 2 diabetes mellitus // Int. J. Innovat. Res. Sci., Engin. Technol. - 2013; 2 (11): 5947-54.
- Ziyadeh F. Mediators of Diabetic Renal Disease: The Case for TGF-β as the Major Mediator // J. Am. Soc. Nephrol. - 2004; 15: 55-7.
- Oh Y.-M., Jeong B.-H., Woo S.-Y. et al. Association of Plasma Adipokines with Chronic Obstructive Pulmonary Disease Severity and Progression // Ann. Am. Thorac. Soc. - 2015; 12 (7): 1005-12.
- Franssen F., O’Donnell D., Goossens G. et al. Obesity and the lung: 5. Obesity and COPD // Thorax. - 2008; 63: 1110-7.
- Maneechotesuwan K., Wongkajornsilp A., Adcock I. et al. Simvastatin Suppresses Airway IL-17 and Upregulates IL-10 in Patients With Stable COPD // CHEST. - 2015; 148 (5): 1164-76.
- O’Byrne P., Rennard S., Gerstein H. et al. Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids // Respir. Med. - 2012; 106: 1487-93.
Supplementary files
